Abstract
Shigellosis is an increasing cause of gastroenteritis in Australia, including prolonged outbreaks in remote Aboriginal and Torres Strait Islander (hereafter “First Nations”) communities and among men who have sex with men (MSM) in major cities. To determine associations between Shigella species and demographic and geographic factors we used negative binomial regression to analyse national case notifications of shigellosis from 2001 to 2019.
S. sonnei and S. flexneri accounted for 42% and 29% of cases, respectively. Nationally, notification rates increased from 2001 to 2019 with yearly incidence rate ratios of 1.04 (95% CI 1.02-1.07) for S. boydii, 1.05 (95% CI 1.04-1.06) for S. sonnei and 1.04 (95% CI 1.04-1.06) for S. flexneri. Children aged 0-4 years had the highest burden of infection for S. flexneri, S. sonnei and S. boydii; and males had a higher notification rate for S. sonnei (incidence rate ratio 1.24, 95% CI 1.15-1.33), reflecting transmission among MSM. First Nations Australians were disproportionately affected by shigellosis, with the notification rate in this population peaking in 2018 at 92.1 cases per 100,000. The findings of this study provide important insights into the epidemiological characteristics of shigellosis in Australia, and can be used to inform targeted public health prevention and control strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We obtained ethical approval for this study from the Australian National University Human Research Ethics Committee [protocol 2018/560] and the ACT Health Human Research Ethics Committee’s Low Risk Sub-Committee [2018/ETH/00158].
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
The data underlying the results presented in the study are from the National Notifiable Diseases Surveillance System. As the data was obtained from a third party, we are unable to upload the minimal data set used in this study. Australian shigellosis notification data, as was used in this study, can be requested from the Communicable Diseases Network Australia. Data requests can be sent to NNDSS.datarequests{at}health.gov.au.